Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTSNASDAQ:COCPNASDAQ:CYCNNASDAQ:DMACNASDAQ:LUMO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$8.58-11.5%$16.35$8.05▼$168.80$3.00M1.057,206 shs11,783 shsCOCPCocrystal Pharma$1.56+0.3%$1.49$1.33▼$3.29$15.87M1.3413,172 shs466 shsCYCNCyclerion Therapeutics$2.87+3.6%$3.09$1.75▼$6.75$7.78M1.843,170 shs156 shsDMACDiaMedica Therapeutics$2.51+2.4%$2.81$1.53▼$4.75$95.28M1.6940,854 shs3,207 shsLUMOLumos Pharma$2.82+0.7%$2.84$2.41▼$4.55$22.90M0.6510,282 shs46,348 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis-4.81%-13.05%-35.47%-50.51%-92.85%COCPCocrystal Pharma-3.97%+4.90%0.00%-3.23%-40.48%CYCNCyclerion Therapeutics+2.17%-12.92%-6.60%-4.71%-49.25%DMACDiaMedica Therapeutics+1.24%-5.77%-8.58%-8.58%+60.13%LUMOLumos Pharma+0.71%+14.63%+1.08%+0.36%-13.76%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytis2.2539 of 5 stars3.55.00.00.01.70.00.6COCPCocrystal Pharma2.175 of 5 stars3.53.00.00.00.71.71.3CYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics1.6034 of 5 stars3.53.00.00.03.30.00.0LUMOLumos Pharma1.514 of 5 stars3.51.00.00.00.02.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis3.00Buy$600.006,893.01% UpsideCOCPCocrystal Pharma3.00Buy$10.00541.03% UpsideCYCNCyclerion TherapeuticsN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.00178.88% UpsideLUMOLumos Pharma3.00Buy$18.00538.30% UpsideCurrent Analyst RatingsLatest BPTS, COCP, CYCN, LUMO, and DMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ACYCNCyclerion Therapeutics$1.62M4.80N/AN/A$4.62 per share0.62DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ALUMOLumos Pharma$2.05M11.17N/AN/A$3.45 per share0.82Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)CYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)DMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)LUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%5/1/2024 (Estimated)Latest BPTS, COCP, CYCN, LUMO, and DMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/A3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A 3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72COCPCocrystal PharmaN/A8.928.92CYCNCyclerion TherapeuticsN/A3.853.85DMACDiaMedica TherapeuticsN/A19.2719.27LUMOLumos PharmaN/A5.695.69OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%COCPCocrystal Pharma6.72%CYCNCyclerion Therapeutics75.62%DMACDiaMedica Therapeutics10.12%LUMOLumos Pharma33.99%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%COCPCocrystal Pharma25.06%CYCNCyclerion Therapeutics13.10%DMACDiaMedica Therapeutics7.20%LUMOLumos Pharma25.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis26350,000338,000Not OptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionableBPTS, COCP, CYCN, LUMO, and DMAC HeadlinesSourceHeadlineContrasting Ainos (NASDAQ:AIMD) and Lumos Pharma (NASDAQ:LUMO)americanbankingnews.com - April 22 at 1:26 AMLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetingsglobenewswire.com - April 18 at 4:05 PMSterlite Technologies to raise Rs 1,000 crore through QIPfinancialexpress.com - April 9 at 3:35 PMLumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomesmarkets.businessinsider.com - March 21 at 3:59 AMLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042globenewswire.com - March 20 at 8:00 AMBAT set to sell stake in India's ITC stake as soon as this week, Bloomberg reportssg.news.yahoo.com - March 11 at 2:00 PMLumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - March 10 at 9:46 AMLumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 9 at 1:25 PMLumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Updatefinanznachrichten.de - March 8 at 3:20 PMLumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 8 at 3:20 PMQ4 2023 Lumos Pharma Inc Earnings Calluk.finance.yahoo.com - March 8 at 10:20 AMLUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023investorplace.com - March 7 at 11:06 PMLumos Pharma: Q4 Earnings Insightsbenzinga.com - March 7 at 6:58 PMLumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Updateglobenewswire.com - March 7 at 4:01 PMEarnings Preview: Lumos Pharmabenzinga.com - March 6 at 7:48 PMLumos Pharma FY 2023 Earnings Previewmsn.com - March 6 at 7:48 PMAxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directorsfinance.yahoo.com - February 28 at 8:03 AMLumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024globenewswire.com - February 26 at 9:00 AMMedplus slips 2% after board defers expansion plan of diagnostics divisionbusiness-standard.com - February 22 at 1:00 AMExact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimatesmsn.com - February 21 at 7:58 PMLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 5 at 9:16 PMLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 5 at 9:16 PMIs Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?finance.yahoo.com - February 5 at 3:53 PMLumos Pharma Elevates Pitukcheewanont to Medical Chiefmarketwatch.com - January 4 at 8:26 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiophytisNASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Cyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Lumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.